key: cord-0774416-imegj0iw
authors: Khan, Muhammad Shahzeb; Shahid, Izza; Anker, Stefan D.; Solomon, Scott D.; Vardeny, Orly; Michos, Erin D.; Fonarow, Gregg C.; Butler, Javed
title: Cardiovascular implications of COVID-19 versus influenza infection: a review
date: 2020-12-18
journal: BMC Med
DOI: 10.1186/s12916-020-01816-2
sha: 5a65e6139a81c23ecbde7b99589988d20e503d43
doc_id: 774416
cord_uid: imegj0iw

BACKGROUND: Due to the overlapping clinical features of coronavirus disease 2019 (COVID-19) and influenza, parallels are often drawn between the two diseases. Patients with pre-existing cardiovascular diseases (CVD) are at a higher risk for severe manifestations of both illnesses. Considering the high transmission rate of COVID-19 and with the seasonal influenza approaching in late 2020, the dual epidemics of COVID-19 and influenza pose serious cardiovascular implications. This review highlights the similarities and differences between influenza and COVID-19 and the potential risks associated with coincident pandemics. MAIN BODY: COVID-19 has a higher mortality compared to influenza with case fatality rate almost 15 times more than that of influenza. Additionally, a significantly increased risk of adverse outcomes has been noted in patients with CVD, with ~ 15 to 70% of COVID-19 related deaths having an underlying CVD. The critical care need have ranged from 5 to 79% of patients hospitalized due to COVID-19, a proportion substantially higher than with influenza. Similarly, the frequency of vascular thrombosis including deep venous thrombosis and pulmonary embolism is markedly higher in COVID-19 patients compared with influenza in which vascular complications are rarely seen. Unexpectedly, while peak influenza season is associated with increased cardiovascular hospitalizations, a decrease of ~ 50% in cardiovascular hospitalizations has been observed since the first diagnosed case of COVID-19, owing in part to deferred care. CONCLUSION: In the coming months, increasing efforts towards evaluating new interventions will be vital to curb COVID-19, especially as peak influenza season approaches. Currently, not enough data exist regarding co-infection of COVID-19 with influenza or how it would progress clinically, though it may cause a significant burden on an already struggling health care system. Until an effective COVID-19 vaccination is available, high coverage of influenza vaccination should be of utmost priority.

cardiovascular disease (CVD) which has been associated with worse prognosis [4] [5] [6] . It has also been suggested that COVID-19 may cause or precipitate myocardial injury and/ or myocarditis and worsen heart failure due to a cytokine storm-related hyper-inflammation syndrome. Similar to SARS-CoV-2, influenza virus also has extensive effects on inflammatory [7] and coagulation pathways and is a wellknown trigger for cardiovascular diseases [7, 8] . In addition to the underlying hyperinflammatory syndrome which is most commonly implicated in cardiovascular complications in both viruses, a substantial component of susceptibility is attributed to host genetics such as host frailty [9] . Although mortality comparisons between influenza and COVID- 19 have been widely drawn, the mortality statistics used to compare the two have been scrutinized [10] . Recent studies suggest that SARS-CoV-2 is more lethal than prior respiratory infections, with a more potent inflammatory response that can possibly trigger more cardiovascular complications [11] . Influenza commonly peaks between December and February [12] . With projections estimating the COVID-19 outbreak to last for another year [13] and influenza season approaching, it is crucial to evaluate the differences in progression of the two diseases in patients prone to cardiovascular complications. In this review, we compare the effects of the two viruses on the cardiovascular system by focusing on the risk factors, short-and long-term complications, and mortality of both influenza and SARS-CoV-2.

PubMed and Scopus were searched to identify relevant studies using the following search terms: [(influenza OR flu) OR (Coronavirus disease 2019 OR COVID-19 OR severe acute respiratory syndrome coronavirus 2 OR SARS-CoV-2)] AND (cardiovascular disease OR cerebrovascular disease OR cardiac abnormality OR cardiac injury OR mortality OR cardiovascular mortality OR cardiac failure OR vascular disease OR stroke OR heart failure OR myocardial infarction OR MI OR ischemic heart disease OR acute coronary syndrome OR myocarditis OR cardiac biomarker OR troponin OR creatine kinase OR thromboembolism OR thrombosis OR vaccine OR prevention). Studies were included if they (1) were pertaining acute (1-7 days since diagnosis) or chronic influenza (> 2 weeks since diagnosis) with concurrent cardiac abnormality, (2) evaluated COVID-19 with concomitant cardiac dysfunction upon presentation or during hospitalization, (3) evaluated short-and/or long-term complications, (4) diagnosed influenza via influenza-like symptoms or serology, and (5) were original studies including observational studies, time-series analysis, case-cross over studies, or meta-analysis. Study designs including case-reports, short case series, commentaries, letter to editors, and editorials were excluded. Main outcomes of interest included (1) mortality, (2) ICU admissions, (3) cardiac biomarkers, (4) vascular complications, (5) cardiac events, (6) stroke, (7) cardiovascular hospitalizations, and (8) prevention strategies. References of relevant review articles were also hand-searched to ensure no relevant studies were missed.

Comparing mortality rates of influenza and COVID-19 is challenging owing to the variances in data accounting for the two diseases. Adult influenza is usually a selflimiting disease; hence, it is often not reported to the public health authorities subsequently leading to underreporting of data. Similarly, lack of testing also poses limitations in reporting of COVID-19 and exact epidemiology of asymptomatic or mild non-specific symptoms related to COVID-19 is not well characterized. Mortality risk comparison between the two is complicated by the adoption of different metrics in comparing mortality statistics between the two diseases [10] . The mortality rate of influenza is most commonly reported as the estimated seasonal influenza deaths reported annually by the Centers for Disease Control and Prevention (CDC) in contrast to raw counts of mortality reported directly for COVID-19 [10] (Fig. 1 ). This may lead to inaccurate conclusion when directly comparing the data. Although limited by failure to account for missing data and yielding premature results, case fatality ratio is being increasingly utilized to highlight the burden of disease in a given population. The overall case fatality ratio of COVID-19 across China after adjusting for censoring, demography, and under-ascertainment has been reported to be 1.38% (95% CI [1.23-1.53]) [14] which is almost 15 times higher than that of seasonal influenza (0.0962%) [15, 16] .

Ten observational studies have reported mortality data of acute influenza concurrent with cardiac abnormality upon presentation. Mortality in individuals hospitalized due to influenza or influenza-like illness ranged from 3.8 to 50% in these studies, with the exception of one study by Chacko et al. [17] evaluating cardiac manifestations in patients with severe H1N1 virus during the 2009 pandemic, where a 92% overall mortality rate was observed (Table 1 ). In contrast to acute influenza, over the course of last 5 months, many (n = 16) observational studies have reported mortality data for patients with COVID-19 infection. The overall mortality in this patient cohort has ranged from 1.4 to 61.5%, which is higher than that observed in patients with acute influenza (Table 1) .

A correlation between cardiovascular mortality and influenza has been suggested by various epidemiological studies. In time-series analyses, an increased mortality due to ischemic heart disease and acute myocardial infarction (MI) has been observed to coincide with peak influenza seasons [8, 41, 42] . Kwong et al. found there was a 6-fold increased risk of MI within 7 days of confirmed influenza diagnosis, compared to a control period [43] . Madjid [41] . Although studies pertaining to acute infection and subsequent mortality are a better indication of a correlation between the disease and mortality, these data are limited by complications which may occur in patients once discharged from hospital and is also difficult to obtain in patients with acute influenza, given the vast under-reporting of the disease.

Given that no time-series analysis pertaining to COVID-19 exists yet, a comparison between both diseases and cardiovascular mortality can be best appreciated by observational studies accounting for the given data. Four influenza studies have reported increased mortality in patients with acute influenza and concomitant cardiac injury. Both Pizzini et al. [25] and Gao et al. [26] reported elevated cardiac biomarkers reflective of myocardial injury (cardiac troponin) upon hospitalization to be associated with increased acute cardiac events and mortality. Death due to myocarditis is also common among patients presenting with influenza. In a retrospective study of 74 patients, To et al. reported myocarditis as the cause of death in 22% of fatal cases [44] . Similar to influenza, increased cardiovascular mortality has been observed in patients with COVID-19. The magnitude of increased risk of cardiovascular mortality with COVID-19 can be best inferred by Zhou et al. [32] study, where non-survivors showed higher rates of acute cardiac injury compared with survivors (59% vs 1%), and study by Guo et al. [5] where highest mortality rate (69.4%) was observed in patients with elevated troponin T and underlying CVD, followed by patients with elevated troponin T and no underlying CVD (37.5%). In another study from Wuhan, China, Shi et al. found that the presence of an elevated high-sensitivity cardiac troponin I was associated with a 4-fold increased risk of death even after adjusting for age and pre-existing CVD [39] .

An association between underlying risk factors, particularly CVD and mortality due to influenza, has been less commonly reported. Two studies [18, 21] have reported no association between mortality and pre-existing CVD, thereby indicating no significance of cardiac history in the exacerbation of disease. This contrasts with data observed in COVID-19 infection, where patients with cardiovascular risk factors appear to be at an increased risk for fatal outcomes associated with COVID-19 disease [5, 32, 34, 39] . About 15 to 70% of COVID-19-related reported deaths have had underlying CVD [5, 32, 34, 38] . Given the adverse outcomes in this patient cohort, this association warrants further research to determine if COVID-19 has a specific predisposition for patients with pre-existing CVD.

Limited data exist for acute influenza with concurrent cardiac abnormality and subsequent ICU admission. Of the six studies [17-20, 26, 45] which have reported ICU admissions for patients with influenza, four studies [17] [18] [19] 45] evaluated clinical progression in patients directly admitted to the ICU. Of the remaining two studies, ICU admissions accorded for 1% and 81% (reporting clinically severe patients during H1N1 pandemic) of all patients hospitalized due to acute influenza [20, 26] (Table 2) . Of all the studies reporting data, median number of ICU stay ranged from 6 to 12 days with 57 to 68% patients requiring invasive mechanical ventilation. Underlying CVD was the most common comorbidity associated with patients requiring ICU care, with pre-existing CVD ranging from 5.4 to 35.2% in this patient cohort [17] [18] [19] [20] 45] .

In contrast to influenza, many studies have reported data for ICU admissions of patients hospitalized due to COVID-19 infection [4, 27, 29, 31-33, 35-37, 39, 40] . The ICU admissions have ranged from 5 to 79% of all patients hospitalized due COVID-19 (Table 2) [4, 27, 29, [32] [33] [34] 37] . Aggregate data from Italy showed that 12% of all COVID-19 hospitalized patients required ICU admission [46, 47] . This is higher than the expected rates of ICU admission for patients due to influenza, whereby approximately 10% of those hospitalized due to severe respiratory distress may require ICU admission [48] . These numbers should be interpreted with caution given that an increasingly higher number of COVID-19 positive patients [50] .

Despite an increased plausible association between cardiovascular comorbidity and increased severity of SARS-CoV-2 [6, 32] , only three studies have evaluated pre-existing CVD for critically ill patients in the ICU. Acute respiratory distress syndrome (ARDS) was the most common complication (60-70%) in patients admitted to ICU, followed by shock (30%), myocardial dysfunction (20-30%) and acute kidney injury (10-30%) [4, 35, 36, 51] . Of all the studies reporting data, approximately 3 to 80% patients required invasive mechanical ventilation. One major complication of both viral infections is the immune susceptibility to secondary bacterial superinfection, which can often lead to adverse outcomes despite initial improvement. Nosocomial infections including ventilator-associated infections are often unavoidable in ICU patients, particularly during a pandemic [52] . During the 2009 H1N1 influenza pandemic, up to 34% of all deaths were due to bacterial coinfections [53] . This highlights the burden of increasing resources needed to curtail this pandemic.

Heterogeneous data exist for cardiac biomarkers evaluating the risk of myocardial injury in patients presenting with influenza (Additional file 1: Table S1A ). Eleven studies have reported at least one cardiac biomarker for patients presenting with acute influenza [17-19, 25, 26, 54-58] . Ludwig et al. [20] showed that among 600 veterans with influenza who had a cardiac biomarker test performed ≤ 30 days after the influenza laboratory test, 143 had a troponin or CK-MB > 99% of the upper reference limit. All these patients had at least one risk factor for CVD, with older veterans with influenza and cardiac injury being more susceptible to cardiac complications at the time of influenza diagnosis [20] . Greaves et al. [58] and Ison et al. [56] reported elevated creatine kinase levels (CK) upon enrollment [56, 58] . Although there are now highly sensitive troponin assays which are more sensitive for detecting cardiac injury compared to conventional troponin assays [59, 60] , only one study evaluated high-sensitivity cardiac troponin T (hs-cTnT) for cardiac injury risk among patients presenting with influenza [25] . Similarly, only one study was found which evaluated D-dimer levels upon hospitalization in patients with acute influenza and myocardial injury [61] . In contrast to influenza, less heterogeneity was noted in cardiac biomarkers evaluating risk of myocardial injury in patients with COVID-19, with fourteen studies reporting at least two cardiac biomarkers for patients hospitalized due to COVID-19 [4, 5, 27, 29, 31-39, 62, 63] . Majority of the studies evaluated hs-cTnT and CK upon hospitalization and included results for D-dimer values (Additional file 1: Table S1B ). An elevated D-dimer value has been independently associated with increased inhospital mortality in patients with COVID-19 [64] . Analysis of the initial studies from China shows a considerable proportion of patients (12-28%) to have elevated cardiac troponin upon hospitalization [4, 5, 32, 36] . This proportion is much higher than that observed in patients presenting with influenza and myocardial injury, thereby indicating a much potent inflammatory response of SARS-CoV-2. In addition to cardiac biomarkers, inflammatory biomarkers such as C-reactive protein, IL-6, and ferritin also provide useful information regarding the underlying hyperinflammatory state of the patient. In SARS-CoV-2, there is an initial phase of disease followed by, in minority of cases, by worsening of the disease that is not related to the viral growth but to the underlying hyperinflammatory state which is less commonly observed in influenza. The timing and subsequent elevation of these aforementioned biomarkers therefore relays the prognostic information of the course of the disease, especially during the first 7-10 days where an increase in these biomarkers may help clinicians to evaluate the severity of the disease. Therefore, for patients presenting with mild increase in cardiac troponin upon hospitalization which may decrease over the course of disease, the cardiac biomarkers reflect an underlying inflammatory response which may resolve over time. In patients who present with increase in cardiac biomarkers during the course of the disease however, the increase may indicate the adverse progression of cytokine-mediated endothelial injury and an unfavorable prognosis. Of note, patients presenting with elevated troponin levels upon admission show higher in-hospital mortality [5, 39] . This was evaluated in a metaanalysis of four studies as well, where the value of troponin I was significantly higher in patients with severe COVID-19 (standardized mean difference (SMD), 25.6 ng/ L; 95% CI, 6.8-44.5 ng/L; I 2 = 98%) compared to those with the milder form of disease [65] . Similar association using robust analysis is yet to be conducted for studies evaluating troponin levels and mortality in patients with influenza.

A markedly increased incidence of intravascular complications, particularly venous and arterial thromboembolic disease, has been reported in patients with severe SARS-CoV-2. In a study by Klok et al. , despite systemic thromboprophylaxis, up to 31% patients developed thrombotic complications, with pulmonary embolism (PE) accounting for the majority of complications [62] . Frequent venous and arterial thrombotic events have been reported in other studies as well, with rates ranging from 27 to 69% for peripheral venous thromboembolism (VTE) and up to 79% for deep vein thrombosis and PE [66] [67] [68] . COVID-19 may predispose patients to intravascular thrombosis due to excessive inflammation increasing the production of clotting factors, coupled with immobilization and pre-existing comorbidities which can significantly contribute to VTE [69] . Although a similar, albeit less potent inflammatory response is noted in patients with influenza, intravascular complications are seldom reported in patients with influenza, with only a few isolated cases of severe H1N1 reporting VTE in critically ill patients [70] [71] [72] . This suggests that vascular thrombosis is an integral part of COVID-19 disease unlike influenza.

The increased severity of vascular complications in COVID-19 can also be inferred by Merkler et al. recent study comparing rate of ischemic stroke between patients with COVID-19 and patients with influenza. After adjustment for covariates, the likelihood of stroke in patients presenting with COVID-19 was 7.5 times higher than patients with influenza (OR 7.5, 95% CI [2.3-24.9]) [11] . Although the pathophysiology remains less well-defined, immune dysregulation and cytokine storm coupled with an attenuated immune response appear to be key components of progression of COVID-19 to critical disease [73] . Timely pharmacologic VTE prophylaxis with lowmolecular weight heparin or unfractionated heparin of high-risk patients is shown to improve outcomes [74] . However, further data is required to evaluate the optimal therapeutic dose of these regimens, given that some studies report VTE events despite standard-dose thromboprophylaxis in patients with COVID-19 [74] .

Several studies have evaluated the potential of influenza to trigger cardiovascular events [75] [76] [77] owing to the underlying mechanism of systemic inflammation which may cause thrombosis after an acute infection [78] . A meta-analysis by Warren-Gash et al. [ [75] . Similar association has been observed in other studies as well [43] (Additional file 1: Table S2 ). For the one study evaluating risk of HF with influenza, three of the seven patients who developed HF were positive for recent influenza [79] . Two case-cross over studies [80, 81] evaluating association between stroke and preceding hospitalization due to influenza-like illness symptoms concluded increased odds of ischemic stroke in the first 15 [80] reported a decrease in the strength of this relationship as days from influenza-like illness increased as opposed to Alvord et al. [81] where the association increased over time.

Currently, no data exist evaluating the chronic cardiovascular effects of SARS-CoV-2 infection months after recovery from acute illness. One study evaluating myocardial injury in patients recently recovered from COVID-19 yielded 78% patients to have residual cardiac involvement, a finding unlikely to be observed in patients after influenza virus, where transient myocardial injury is more commonly associated with acute viremic phase [82] . Given the similar pathophysiology between the two viruses, whereby an aggravation of systemic inflammatory cytokines lead to cytokine-storm syndrome, a phenomenon commonly responsible for severe COVID-19 [83] , induction of new cardiac pathologies or exacerbation of pre-existing CVD is likely [6] . High inflammatory burden can induce vascular inflammation rapidly, which can promote development of atherosclerosis, cardiac arrhythmia, and myocarditis [6] . A much higher burden of cardiovascular complications post COVID-19 compared with influenza can therefore be anticipated, owing to the more potent underlying inflammatory response of SARS-CoV-2.

Peak influenza season has been associated with increased cardiovascular hospitalizations [84] [85] [86] . In a study by Kytomaa et al. [86] , community surveillance data used to analyze frequency of MI and heart failure hospitalizations and its association with monthly influenza activity revealed a 5% monthly increase in influenza activity to be associated with a 24% increase in HF hospitalizations (incidence rate ratio [IRR], 1.24; 95% CI, 1.11-1.38; P < .001) [86] . Conflicting results exist regarding MI hospitalization [85, 86] . A timeseries analysis by Warren-Gash et al. [85] demonstrated a significant association between MI hospitalization and influenza-like illnesses' consultations in England (IRR for a lag of − 1 week, 1.009 [95% CI, 1.003-1.015; P = .004] and proportion of influenza-positive specimens in Hong Kong (IRR for same week, 1.066; 95% CI, 1.024-1.109; P = .002); however, no significant association was observed in the study by Kytomaa et al. [86] (Additional file 1: Table S3 ).

These trends contrast with that observed during the current COVID-19 pandemic, where a decrease of5 0% in heart failure hospitalizations has been observed since the first diagnosed case of COVID-19 [87] . Similar downward trajectory has been observed across acute cardiovascular hospitalizations, where a significant decline in daily hospitalization rate was observed throughout March 2020 (− 5.9% per day [− 7.6 to − 4.3%], P < 0.001) [88] . These reductions were observed despite a significantly large increase in mortality (up to 90%) due to CVD during this time period, with a transient two-time increase in the incidence of out of hospital cardiac arrests [89, 90] . This signifies that a decrease in hospitalizations may largely be attributed to patient fear of seeking healthcare in a medical facility due to concerns of contracting the virus, which are further substantiated by increased inculcation of physical distancing and isolation. The consequences of avoiding emergent care are greater than the risks imposed by seeking care in a medical facility, and the detrimental effects of delaying appropriate medical care often lead to poor prognosis in these patients. It is crucial to acknowledge that an increase in out-of-hospital cardiac arrests and sudden death signifies that the reduction of cardiovascular hospitalization was not benign, and can have significant consequences in the future if not timely prevented. These stringent measures of social isolation are not commonly adopted to curb transmission of influenza virus, even during peak influenza season; hence, people may not be hesitant to seek medical care which may explain the opposing trajectories of hospitalization observed in the two diseases.

The most effective and cost benefit prophylaxis of influenza virus is the seasonal influenza vaccine. Although the effectiveness of vaccine may vary among groups, recent studies have shown that influenza vaccine reduces the risk of flu by 40-60% during peak influenza seasons [91] . During the 2017-2018 seasonal influenza, an estimated 3.2 million influenza-associated medical visits, 91, 000 influenza-associated hospitalizations, and 5700 influenza-associated deaths were prevented due to adequate vaccination prior to the season [91] . In terms of safety, almost all influenza vaccines on the market are well-tolerated [92, 93] and adverse effects are uncommon and usually mild [94] .

In addition to preventing the virus, influenza vaccine has also been implicated in preventing major adverse cardiovascular outcomes [95] [96] [97] [98] . In a study by Udell et al. [95] , pooled data from six randomized clinical trials indicated influenza vaccine to be associated with a lower risk of composite cardiovascular events (2.9% vs 4.7%; RR, 0.64 [95% CI, 0.48-0.86], P = .003) [95] . Considering the link of influenza virus and increased risk of MI, the potential protective effect of influenza vaccine in prevention of adverse cardiovascular outcomes is of paramount clinical importance.

Given the high transmission and reproduction number (R 0 2.2) of SARS-CoV-2 coupled with its ability to cause a pandemic disease within weeks, a possibility to curb this virus without a vaccine seems highly challenging. Currently, numerous vaccines to combat COVID-19 are under clinical evaluation while over a hundred vaccines are undergoing pre-clinical evaluation [99] . Developing a novel vaccine which is safe and effective in a short time frame poses its own challenges. One of the obstacles in early development of SARS coronavirus vaccines has been the finding of undesired immunopotentiation which often occurs after immunizations with whole virus or complete spike protein vaccines [28, 100] . Second, there is also heightened concerns regarding the adverse effects these vaccine trials might pose such as exacerbating ongoing lung and cardiovascular diseases [101] . Given that the most vulnerable population such as healthcare workers and elderly will be prioritized for these vaccine trials, it is crucial to accurately determine and review the safety before these subgroups are exposed to it. Third, vaccine development is a lengthy and expensive process due to the high failure rates which raises concerns as to whether the vaccine will be developed in time to combat this pandemic [101] . One way to counter this is by using a "pandemic paradigm," which supports multiple activities during vaccine development to be executed in parallel before confirming a successful outcome of the another step [101] . For example, human phase 1 clinical trials can proceed parallel to ongoing testing in animal models [101] .

Considering that clinical trials for influenza vaccines first began in mid-1930s [102, 103] , and the first bivalent vaccine which provided proof of effective protection against flu epidemics became available in December 1942 [104, 105] , it is likely that we might be years from developing an effective vaccine to prevent COVID-19. The past research on SARS and Middle East respiratory syndrome (MERS) may help fast-track the development of potential vaccine.

Until a vaccine is available, the most effective barriers in reducing transmission risk of SARS-CoV-2 include physical distancing, hand hygiene, and facemask protection [106] . Strong evidence suggests wearing facemasks can efficaciously reduce virus particles in respiratory droplets. Study by Stutt et al. concluded that the use of routine facemask by up to half of the population can reduce R value to less than 1.0, thereby preventing the possibility of another wave [107] . These measures of protection extend well beyond SARS-CoV-2, by also mitigating risk of transmission of influenza virus. Adopting facemask protection at a population level can effectively decrease the influenza infection attack rate (R int ) beyond the threshold of 1.0, thereby controlling the possibility of an influenza pandemic [108] . Adequate compliance of these measures is therefore crucial in an effort to delay or contain the possibility of a dual epidemic.

Although speculative, if COVID-19 vaccine is as effective as influenza vaccine, it may additionally reduce adverse cardiovascular events owing to the suppression of acute inflammatory and procoagulant stimulus, a mechanism postulated in prevention of alteration in endothelial function and consequent destabilization of vulnerable atherosclerotic plaques which may contribute to coronary artery occlusion in influenza vaccine [109] . This can serve as a possible secondary prevention for individuals with underlying CVD, who are susceptible to recurrent cardiovascular events due to COVID-19 infection.

Although maximum efforts were utilized to collate all available evidence, there are a few limitations that should be considered. First, we only included major observational studies evaluating influenza or COVID-19 concurrent with cardiac abnormality, thereby excluding data available within case-series or case reports. Second, majority of the studies included were retrospective in design, which are subject to bias due to missing information or recall error. Third, since influenza is a self-limiting disease, majority cases often go unreported with only patients with severe illness requiring emergency care as opposed to COVID-19, where majority of those infected were hospitalized. This also signifies the severity of underlying disease. Fourth, studies involving COVID-19 were from China and the USA only, and thus, their findings cannot be generalized to other regions. Fifth, we offer an indirect comparison between COVID-19 and influenza, by including studies evaluating disease progression in different centers during different time period. Final, no studies including patient population co-infected with COVID-19 and influenza were analyzed, which can potentially cause a different trajectory of disease progression.

This review highlights the similarities and differences between influenza and COVID-19 and the potential risks associated with coincident pandemics (Fig. 2) . COVID-19 has a higher mortality and case fatality rate and has increased risk of adverse outcomes especially in patients with underlying CVD. Vascular complications including DVT and PE are markedly higher in COVID-19 patients suggesting that vascular thrombosis is an integral part of the disease unlike influenza. The decreased rates of hospitalization during COVID-19 pandemic further pose a threat to patients who experience diseases which require prompt in-hospital treatment such as myocardial infarction or stroke, where a possible delay in care can lead to permanent impairment. In the coming months increasing efforts towards evaluating new interventions will be vital to curb COVID-19 especially as peak influenza season approaches. It is crucial to acknowledge that the higher number of patients hospitalized due to COVID-19 globally, ranging from moderate to severe disease gives physicians and researchers alike an opportunity to look at relatively rare complications with much more clarity and granularity when compared with acute influenza, where hospitalizations are much less common leading to paucity of data pertaining rare complications of the disease. Given the similar clinical presentation of both viruses, timely detection by accurately distinguishing COVID-19 from influenza pneumonia through imaging can help in early management of these patients. Currently, not enough data exist regarding coinfection of COVID-19 with influenza or how it would Fig. 2 Overall comparison between influenza and COVID-19. *Contrary to influenza, a transient two times increase in out of hospital cardiac arrests was observed during COVID-19 pandemic period, suggesting indirect effects of lockdown and reluctance of patients to present to the hospital out of fear of contamination progress clinically though it may cause a significant burden on an already struggling health care system. Until an effective COVID-19 vaccination is available, high coverage of influenza vaccination should be of utmost priority to ensure patient safety and prevent the possibility of a co-epidemic [110] , which poses as a major health threat to non-infected patients with underlying CVD. Government, hospital administrators, and policy makers should work together to prepare for a substantial increase in health care resources, and multinational collaborations should be encouraged to advance high quality research to combat this pandemic and its associated downstream cardiovascular and other health complications.

The online version contains supplementary material available at https://doi. org/10.1186/s12916-020-01816-2.

Additional file 1: 

A novel coronavirus from patients with pneumonia in China

An interactive web-based dashboard to track COVID-19 in real time

Restructured society and environment: a review on potential technological strategies to control the COVID-19 pandemic

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Potential effects of coronaviruses on the cardiovascular system: a review

Influenza and cardiovascular disease: is there a causal relationship?

Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects

Host susceptibility to severe influenza A virus infection

Assessment of deaths from COVID-19 and from seasonal influenza

Risk of ischemic stroke in patients with Covid-19 versus patients with influenza

Covid-19: outbreak could last until spring 2021 and see 7.9 million hospitalised in the UK

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Estimated influenza illnesses, medical visits, hospitalizations, and deaths in the United States -2018-2019 influenza season

Likelihood of survival of coronavirus disease 2019

Cardiac manifestations in patients with pandemic (H1N1) 2009 virus infection needing intensive care

Myocardial dysfunction during H1N1 influenza infection

Transient cardiac injury during H7N9 infection

Acute cardiac injury events ≤30 days after laboratory-confirmed influenza virus infection among U.S. veterans

Frequency of troponin elevations in patients with influenza infection during the 2017-2018 influenza season

Effect of influenza on outcomes in patients with heart failure

Outcomes of acute myocardial infarction in patients with influenza and other viral respiratory infections

Relation of concomitant heart failure to outcomes in patients hospitalized with influenza

Prognostic impact of high sensitive troponin T in patients with influenza virus infection: a retrospective analysis

Association between cardiac injury and mortality in hospitalized patients infected with avian influenza A (H7N9) virus

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

The SARS-CoV-2 vaccine pipeline: an overview

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Clinical characteristics of Covid-19 in

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of coronavirus disease 2019 in China

Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study

Seasonal influenza infections and cardiovascular disease mortality

Influenza and the winter increase in mortality in the United States, 1959-1999

Acute myocardial infarction after laboratory-confirmed influenza infection

Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection

Outcomes of patients with severe influenza infection admitted to intensive care units: a retrospective study in a medical Centre

Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response

COVID-19 and Italy: what next?

Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza

Epidemiological features of influenza in Canadian adult intensive care unit patients

Differentiation of COVID-19 from seasonal influenza: a multicenter comparative study

Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations

Secondary bacterial infections in patients with viral pneumonia

Bacterial coinfection in influenza: a grand rounds review

Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China

The prevalence and findings of subclinical influenza-associated cardiac abnormalities among Japanese patients

Cardiac findings during uncomplicated acute influenza in ambulatory adults

Echocardiographic manifestations of pandemic 2009 (H1N1) influenza a virus infection

The prevalence of myocarditis and skeletal muscle injury during acute viral infection in adults: measurement of cardiac troponins I and T in 152 patients with acute influenza infection

Interferon treatment for dilated cardiomyopathy and striated myopathy associated with hepatitis C virus infection based on serial measurements of serum concentrations of cardiac troponin T

Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates

Serum D-dimer changes and prognostic implication in 2009 novel influenza A(H1N1)

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

D-dimer levels on admission to predict inhospital mortality in patients with Covid-19

Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19)

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Thromboembolic events in patients with severe pandemic influenza A/H1N1

Pandemic H1N1 influenza infection and vascular thrombosis

Acute thrombotic vascular events complicating influenza-associated pneumonia

Applying the lessons of influenza to COVID-19 during a time of uncertainty

Prophylaxis and treatment of venous thromboembolic disease in COVID-19 -American College of Cardiology n

Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review

The cardiovascular manifestations of influenza: a systematic review

Influenza, influenza-like symptoms and their association with cardiovascular risks: a systematic review and meta-analysis of observational studies

Inflammation and coagulation in the cardiovascular system: the contribution of influenza

Coxsackie virus infection in acute myocardial infarction

Influenza-like illness as a trigger for ischemic stroke

Abstract 189: Influenza-like illness and risk of stroke

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Acute myocardial infarctions, strokes and influenza: seasonal and pandemic effects

Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong

Association of influenza-like illness activity with hospitalizations for heart failure: the atherosclerosis risk in communities study

Reductions in heart failure hospitalizations during the COVID-19 pandemic

Declines in hospitalizations for acute cardiovascular conditions during the COVID-19 pandemic: a multicenter tertiary care experience

Out-of-hospital cardiac arrest during the COVID-19 pandemic

Excess deaths from COVID-19 and other causes

Vaccine effectiveness: how well do the flu vaccines work?

Efficacy and safety of high-dose influenza vaccine in elderly adults: a systematic review and meta-analysis

A systematic review and metaanalysis on the safety of newly adjuvanted vaccines among children

Influenza Vaccine for 2019-2020

Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis

The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial

Influenza vaccination and secondary prevention of cardiovascular disease among Taiwanese elders-a propensity score-matched follow-up study

The association of influenza infection and vaccine with myocardial infarction: systematic review and meta-analysis of self-controlled case series

World Health Organisation. Draft landscape of COVID-19 candidate vaccines

Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome

Developing Covid-19 vaccines at pandemic speed

The search for the ideal influenza vaccine

Vaccination against influenza

Protective effect of vaccination against induced influenza A

An overview of the regulation of influenza vaccines in the United States. Influenza Other Respir Viruses

Respiratory virus shedding in exhaled breath and efficacy of face masks

A modelling framework to assess the likely effectiveness of facemasks in combination with 'lock-down' in managing the COVID-19 pandemic

The effect of mask use on the spread of influenza during a pandemic

Influenza and atherosclerosis: vaccination for cardiovascular disease prevention

The dual epidemics of COVID-19 and influenza: vaccine acceptance, coverage, and mandates

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Not applicable.Author disclosures Stefan D Anker: has received research support from Vifor International & Abbott Vascular, and fees for consultancy and/or speaking from Astra Zeneca, Bayer, Boehringer Ingelheim, Respicardia, Impulse Dynamics, Janssen, Novartis, Servier and Vifor Scott D Solomon: Dr. Solomon has received research grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Lone Star Heart, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, Respicardia, Sanofi Pasteur, Theracos, and has consulted for Abbott, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, Gilead, GSK, Ironwood, Lilly, Merck, Myokardia, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardurion, AoBiome, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna Orly Vardeny: has received research grants from AstraZeneca and Bayer, and has consulted for Sanofi-Pasteur Gregg Fonarow: Consulting for Abbott, Amgen, AstraZeneca, Bayer, Janssen, Medtronic, Merck, and Novartis. Javed Butler: consultant for Abbott, Amgen, Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squib, CVRx, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Relypsa, Vifor. All other authors report no disclosures.

Authors' contributions MSK and JB developed the concept of the article. All authors contributed in critically reviewing/analyzing the data, writing the manuscript, and providing comments on the draft and approved the final manuscript. All authors are responsible for the overall contents of the article.

Not applicable.

All data generated or analyzed during this study are included in this published article [and its supplementary information files].Ethics approval and consent to participate Not applicable.

Not applicable.

The authors declare that they have no competing interests.